Showing 2769 results
-
Press release /Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…
-
Press release /Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
-
Press release /Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
-
Press release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Press release /Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
-
Press release /Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
-
Press release /Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening…
-
Press release /European Medicines Agency validated MAAs for tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indicationsSubmissions based on data from Phase III RATIONALE…